|Bid||43.55 x 1300|
|Ask||44.45 x 800|
|Day's Range||41.67 - 44.25|
|52 Week Range||30.10 - 67.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||60.50|
NEW YORK, NY / ACCESSWIRE / June 19, 2018 / U.S. markets finished mostly lower on Monday, with the Dow logging its 5th straight decline, on fears of growing trade tensions between the U.S. and China. The ...
The surprise departure of its long-time CEO and the recent approval of two new drugs have investors wondering if a deal is coming.
SOUTH SAN FRANCISCO, Calif., June 05, 2018-- Portola Pharmaceuticals, Inc. ® today announced that the company will present at the following conferences in June:. Goldman Sachs 39 th Annual Global Healthcare ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 4) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ANGO ...
Portola Pharmaceuticals, Inc.® (PTLA) today announced that William Lis has informed the Board of Directors of his plans to retire as Chief Executive Officer and member of the board. Mr. Lis will continue to serve as CEO and member of the board through August 1, 2018 to ensure a smooth transition, after which time he will remain in an advisory role. Mr. Lis joined Portola in 2008.
See which stocks are posting big moves after the bell Monday: Shares of Starbucks SBUX dropped 1.4 percent in extended trading, after Executive Chairman Howard Schultz announced he would be stepping down effective June 26.
–Differentiated SYK-JAK Inhibitor Shows Efficacy in Patients with Heavily Pre-Treated B- and T-Cell Malignancies–. –New Signal in AITL; Five Complete Responses for a Complete Response Rate of 71 Percent–. ...
Portola Pharmaceuticals, Inc.® (PTLA) today announced that the company has received a $100 million milestone payment from HealthCare Royalty Partners (HCR) following the U.S. Food and Drug Administration (FDA) approval of Andexxa [coagulation Factor Xa (recombinant), inactivated-zhzo] on May 3, 2018. In February 2017, Portola entered into a $150 million royalty agreement with HCR in exchange for a tiered, mid-single-digit royalty based on worldwide sales of Andexxa.
On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.28. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
--Conference Call Today at 4:30 p.m. ET--. SOUTH SAN FRANCISCO, Calif., May 09, 2018-- Portola Pharmaceuticals, Inc. ® today reported financial results for the three months ended March 31, 2018 and provided ...
Short interest is low for PTLA with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 15.
How far off is Portola Pharmaceuticals Inc (NASDAQ:PTLA) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock isRead More...
LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free research report on Portola Pharma, Inc. (NASDAQ: PTLA), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=PTLA as the Company's latest news hit the wire. On May 03, 2018, the Company announced that the US Food and Drug Administration (FDA) has approved its lead candidate, Andexxa®, the first and only antidote indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. Active-Investors.com is currently working on the research report for China Biologic Products Holdings, Inc. (NASDAQ: CBPO), which also belongs to the Healthcare sector as the Company Portola Pharma.
NEW YORK, NY / ACCESSWIRE / May 7, 2018 / Pharmaceutical companies ACADIA and Portola saw their shares bursting on Friday. ACADIA moved higher on strong first quarter results of its Parkinson’s Disease drug Nuplazid while Portola soared higher after receiving FDA approval for Andexx, an anticoagulant-reversal antidote.
Both of the company's drug approvals over the past year are for drugs discovered and developed by its own scientists.
Portola said the FDA approved its andexanet alfa, a factor Xa inhibitor reversal agent. The FDA had issued a complete response letter for the drug's biologics license application in August 2016. Portola shares came under selling pressure yet again March 1, when the company indicated on its fourth quarter earnings call that the FDA sought additional data that could necessitate an additional trial.
Case in point: Portola Pharmaceuticals (NASDAQ:PTLA), whose shares are jumping nearly 20% on Friday. Why the excitement? The volatile drug maker announced that the FDA has approved its lead candidate Andexxa, developed to reverse anticoagulation for Factor Xa inhibitors. “Today’s approval represents a significant step forward in patient care and one that the medical community has been eagerly anticipating,” said Stuart J. Connolly, M.D., ANNEXA-4 Executive Committee chairman and professor in the Department of Medicine of the Faculty of Health Sciences at McMaster University in Hamilton, Ontario.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Tyson Foods, Inc. (NYSE: TSN ) stock could see increased ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on May 3) ABIOMED, Inc. (NASDAQ: ABMD ) (reported better-than-expected ...